Lunaphore Technologies

Executive Summary

Lunaphore Technologies is a Swiss spatial biology company that has developed a fully automated platform for multiplex immunofluorescence and immunohistochemistry, targeting the rapidly growing immuno-oncology research market. Founded in 2014 and based in Lausanne, the company aims to democratize spatial biology by providing scalable, flexible, and accessible tools that enable researchers to gain deep insights into the tumor microenvironment and immune cell interactions. Lunaphore's technology promises to accelerate discovery and drug development by replacing manual, low-throughput methods with high-parameter, automated workflows that can be adopted by laboratories of all sizes. The company is privately held and has not disclosed total funding, but its platform has the potential to capture significant market share in the spatial biology space, which is projected to expand as precision oncology and biomarker discovery become more central to pharmaceutical R&D. Lunaphore's competitive edge lies in its focus on automation and ease of use, which address key bottlenecks in existing spatial analysis techniques.

Upcoming Catalysts (preview)

• Q4 2026Commercial launch of next-generation high-plex platform60% success
• Q2 2027Strategic partnership with major pharmaceutical or diagnostics company50% success
• Q1 2027Series B or C funding round to scale manufacturing and sales70% success